Research in gene therapy and other areas in recent years has led to many significant advances in efforts to develop new curative therapies for a range of serious diseases and conditions. Products including Kymriah, Yescarta, and Luxturna have been launched, and many others are advancing to late stage development. In this article published in Managed Healthcare Executive, Matthew Majewski considers new options for pricing models to keep pace with innovation in the development of high-cost gene, cell therapies.
To read the article, click here.
Rebalancing resources for healthcare and medicines: How much is enough?
This report identifies two key policy objectives that can be generated from healthcare and pharmaceutical spending.